JUNS - Jupiter Neurosciences
Printed from CEF Radar (cefradar.com). Source: public filings at the U.S. Securities and Exchange Commission. Last checked: Nov 3, 2026, 8:10 a.m. New York time.
JUNS is a company, not a closed-end fund. We still track it - notices about it are below - but most of this site is about funds.
Is anyone targeting this fund?
Yes - one large investor holds a stake, but it has not asked for changes.
- PharmAla Biotech Holdings owns 10.1% as a passive investor. On file since Sept 22, 2026.
What this means for you
One large investor owns more than 5% of this company but has told the regulator it is not seeking changes. That is common for banks, brokers and index funds that hold shares for their clients.
Nothing is required of you. If an investor changes its mind, it must file a new notice within days, and it will show up here.
What happened, and when
-
Oct 26, 2026
PharmAla Biotech Holdings cut its stake to 10.1% (from 17.3%), as a passive investor.
Original document → -
Sept 22, 2026
PharmAla Biotech Holdings now owns 17.3%, as a passive investor.
Original document →
Details: all notices, events and fund facts
| Date | Investor | Stake | Type of notice |
|---|---|---|---|
| Oct 26, 2026 | PharmAla Biotech Holdings | 10.1% | Updated notice |
| Sept 22, 2026 | PharmAla Biotech Holdings | 17.3% | Passive investor |
No announcements from the fund on file. Most funds announce their payout on their own website, not in a filing with the regulator, so a cut or a raise there does not show up here.
- Run by
- not filed yet
- Fund family
- not filed yet
- Exchange
- Nasdaq
See this fund's page at the SEC →
Email me when something new is filed for JUNS
Free. One email when a large investor files a notice, or when the fund announces a buy-back, a vote or a closing - usually within a day. No password. Most funds announce payout changes on their own website, where we do not look.